Real-World Treatment Study of Koselugo (Selumetinib) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Real-World Treatment Study of Koselugo (Selumetinib) — Stella

Home/Neurofibromatosis 1/

View on ClinicalTrials.gov

Recruiting

Back to Neurofibromatosis 1 trials

Trial locations(12 sites)

South Korea

Research Site, Busan

Research Site, Chungcheongbuk-do

Research Site, Daejeon

Research Site, Gyeonggi-do

Research Site, Incheon

Research Site, Jeonnam

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul

Research Site, Wŏnju

Research Site, Yangsan

Key details

Sponsor

AstraZeneca

Enrollment target

~200 participants

Started

June 2024

Primary completion

September 2031

Age range

3 Years – 99 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.